Three-Year NHS Study Shows Blood Test Reduces Stage IV Cancer Diagnoses
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
The CLIA-certified facility offers functional precision medicine testing that analyzes live tumor cells against FDA-approved therapies within 10 days.
A longitudinal study finds blood-based biomarkers more sensitive than PET scans in detecting obesity's impact on Alzheimer's pathology.
Hims & Hers Health is now offering GRAIL’s Galleri multi-cancer blood test through its digital health platform, expanding access to screening for more than 50 cancer types, including those lacking established protocols.
Vanderbilt Medical Laboratories has implemented in-house rapid antigen testing for histoplasmosis, reducing turnaround times and improving patient management, according to clinical staff and recent case reports.
The company will process clinical samples for Path Fertility’s NOA Guide, an epigenetic test designed to inform surgical decision-making for men with non-obstructive azoospermia.
The test is being developed to differentiate between adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis at the point of care.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
A large-scale international trial is evaluating a finger prick blood test for Alzheimer’s, analyzing three protein biomarkers as a potential alternative to PET scans and lumbar punctures.
Babson Diagnostics’ BetterWay GLP-1 blood testing panel is now available at more than 25 Austin and Temple, Texas, retail locations, including Sam’s Club and Peoples Rx pharmacies. The panel features 29 tests to support GLP-1 therapy.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The eight-minute test also shortened hospital stays by nearly two days at Froedtert Hospital, reinforcing previous multi-site evidence.